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Table S1a (related to Table 1). In vitro kinase selectivity of compound 14. 
Kinase IC50 (μM)a 
Bcr-Abl 4.4 ± 0.2 
Akt/PKB > 10 
CaMKII > 10 
CK2 > 10 
ERK-2 > 10 
GSK3b 0.39 ± 0.04 
Lck 1.9 ± 0.1 
PDGFb 0.80 ± 0.09 
Plk1 > 10 
PKA > 10 
PKC > 10 
S6 8.6 ± 3.7 
SAPK2a > 10 
Src 2.0 ± 0.1 
VEGFR2 0.18 ± 0.02 
Aurora A 0.65 ± 0.06 
Aurora B 0.40 ± 0.13 
a Mean ± SD of at least two independent determinations; [ATP] = 0.1 mM. 
Table S1b (related to Table 1). Biopharmaceutical and pharmacokinetic properties of 
compound 14. 
In vitro biopharmaceutical properties 
Partition coefficient LogD7.4a 1.1 
Dissociation constants pKab 8.3, 3.1 
Aqueous solubilityc > 100 μM 
Intestinal permeability Pappd (10-6 cm/s)  2.4 
CLint (mL/min/mg) 27.5 Microsomal stabilitye 
t1/2 (min) 50 
2 
Plasma protein bindingf 
Fraction bound 
(%) 
64 
Rat pharmacokinetics 
Pharmacokinetic parameter 5 mg/kg iv 50 mg/kg po 
Exposure AUC0-24h (h.μM) 1.5 10.4 
Elimination t1/2 (h) 1.0 4.9 
Clearance  CL (L/h/kg) 8.7 12.2 
Volume of distribution  Vz-F (L/kg) 126 97 
Oral bioavailability  (% F)  70 
a Partitioning between octanol and aqueous buffer using the shake-flask method; b de-
termined using a pH-metric method; c by turbidimetry; d apparent permeability coefficient 
measured using a Caco-2 cell layer assay; e measured by disappearance of parent com-
pound (LC-MS) from a preparation of rat liver microsomes; f rat plasma protein binding 
using an equilibrium dialysis assay. 
 
 
Table S1c (related to Table 1). Antiproliferative activity of compound 14. 
Human cell line 
Origin Designation 
72-h MTT 
IC50 ± SD (nM) 
Saos-2 386 ± 189 Bone osteosarcoma 
U2OS 372 ± 69 
MDA-MB-468 221 ± 56 
Breast 
MCF-7 490 ± 358 
Cervix Hela 401 ± 154 
HT29 280 ± 73 
LOVO 218 ± 118 
NCI-H1299 501 ± 207 
Colon 
HCT-116 180 ± 44 
Gastric adenocarcinoma AGS 256 ± 104 
Leukemia CCRF-CEM 577 ± 438 
Promyelocytic leukaemia HL60 374 ± 25 
A549 299 ± 93 
Lung 
NCI-H460 264 ± 146 
SKUT-1B 107 ± 43 
Leiomyosarcoma 
SKUT-1 225 ± 75 
Neuroblastoma SK-N-MC 149 ± 24 
Ovarian carcinoma A2780 131 ± 9 
Pancreatic carcinoma Mia-Paca-2 139 ± 9 
Prostate DU-145 140 ± 17 
Skin keratinocyte Hacat 351 ± 122 
Messa 150 ± 16 
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Uterine 
Messa-Dx5 536 ± 260 
IMR-90 12,278 ± 1,422 
Untransformed Foetal lung fibroblast 
WI38 5,748 ± 3,123 
Mean transformed 293 
Median transformed 264 
Mean untransformed 9013 
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Table S2 (related to Figure 3). Selective induction of apoptosis in transformed cells by 
CDK9-selective compounds. 
Treatment % Cells TUNEL-positivea 
Test compound Concentration (μM) A2780 
(Transformed) 
WI-38 
(Untransformed) 
0.2 8 NT Compound 3 
1.0 63 3 
1.0 6 NT 
Compound 9 
5.0 69 17 
1.0 2 NT 
Compound 10 
5.0 53 10 
Control 1 0 
a TUNEL analysis of treated cells. A2780 or cycling WI-38 cells were treated with com-
pounds for 24 h. Cells were analysed for DNA strand breaks by the TUNEL method. The 
percentages of cells labelled as TUNEL-positive are shown. All compounds show a greater 
selectivity for the transformed line over the untransformed one. NT-not tested. 
 
Table S3 (related to Figure 4). Data collection and refinement statistics for X-ray crys-
tal structure complexes of CDK2 with compounds 11 and 14. 
Data collection CDK2-compound 11 CDK2-compound 14 
Space group P212121 P212121 
Unit cell dimensions; a, b, c (Å) 53.12, 71.50, 71.64 53.00, 71.11, 72.03 
Maximum resolution (Å) 1.9 1.8 
Total observations 67,708 67,264 
Unique reflections 21,623 25,565 
Completeness (%) 97.9 98.8 
Rmerge 0.078 0.075 
<I / σ I> 7.9 7.3 
Rmerge, highest resolution bin 0.415 0.485 
<I / σ I>, highest resolution bin 2.3 2.1 
Refinement   
Protein atoms 2,404 2,487 
Ligand atoms 58 54 
Water molecules 255 271 
Reflections used in refinement 20,724 22,796 
Rwork 18.9 21.1 
Rfree 27.1 29.5 
Mean B-factor, protein (Å2) 52.1 48.8 
Mean B-factor, ligands (Å2) 57.8 40.2 
Mean B-factor, solvent (Å2) 58.5 53.4 
Bond lengths from ideal values 
RMSD (Å) 
0.011 0.012 
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Bond angles from ideal values  
RMSD (degrees) 
1.69 1.60 
 
 
 
Figure S1a (related to Figure 1). Identification of CDK transcriptional inhibitors 
by cell-based assays. Cells were treated with a set of 220 test compounds from our 2-
anilino-4-(heteroaryl)pyrimidine kinase inhibitor compound library (Wang et al., 2004a; 
Wang et al., 2004b; Wu et al., 2003) or assay diluent only (DMSO control) at 10 µM for 7 
h. MI was measured by determining the percentages of phospho-histone-H3 positive U2-
OS cells. Nuclear accumulation of p53 was assessed by immunofluorescent staining in 
5 
MCF-7 cells. Phenotypic classification is indicated: unclassified; class 1 (transcriptional 
inhibitors); class 2 (mitotic inhibitors); class 3 (cell cycle inhibitors). 
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Figure S1b (related to Figure 1). Induction of histone H2AX phosphorylation. 
Compound 1 does not induce phosphorylation of histone H2AX, (a classical marker of 
DNA damage) at early time points in contrast to the DNA damaging agent doxorubicin. 
Cells were treated with compounds or assay diluent only (control) at the concentrations 
indicated for 7 h. 
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Figure S1c (related to Table 1). Human kinase assay panel for compound 14. 
The assays were carried out using appropriate protein or peptide substrates and at ATP 
concentrations near the Km,ATP for the individual kinases (5 – 50 μM). 
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Figure S2a (related to Table 1). In vivo antitumour activity of compound 14 in 
the murine P388/0 survival model. Groups of animals were dosed ip with compound 
14 twice daily for ten days. 
 
 
 
 
 
 
 
 
Figure S2b (related to Table 1). In vivo antitumour activity of compound 14 in 
the Colo-205 xenograft model. Compound 14 was administered once daily for 8 days. 
The positive control chemotherapy agent 5-FU was given using an optimal dose and 
schedule for the Colo-205 model. Tumour versus control ratios (% T/C) on days 29, 32 
and 36: 85, 75 and 62% (5-FU); 45, 36 and 35% (14, 50 mg/kg ip); 49, 41 and 38% 
(14, 100 mg/kg po). Maximal growth delay (T – C) was 15 days (14, 50 mg/kg ip) and 
12 days (14, 100 mg/kg po). 
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Figure S3 (related to Figure 5). Cellular effects of CDK9-selective compounds. 
A2780 cells were treated with compounds 3, 9 and 10 for 3 hours. These compounds 
represent molecules with a greater selectivity for CDK9 over CDK7 compared to 14. Each 
compound can reduce the phosphorylation of RNAP-II CTD at Ser-2, induce p53, and re-
duce levels of Mcl-1. 
 
Supplemental Experimental Procedures 
Synthesis and compound characterisation 
3-[4-(2-Ethylamino-4-methyl-thiazol-5-yl)-pyrimidin-2-ylamino]-benzenesulfonamide 
(2). By condensation of 3-dimethylamino-1-(2-ethylamino-4-methyl-thiazol-5-yl)-
propenone and nitrate of 3-guanidino-benzenesulfonamide. Yellow solid; mp: 148-150 
°C; anal. RP-HPLC (0-60% MeCN): tR = 13.1 min; 1H-NMR (500 MHz, DMSO-d6): δ 1.18 
(t, J = 7.5 Hz, 3H), 2.48 (s, 3H), 3.27 (m, 2H), 6.94 (d, J = 6.0 Hz, 1H), 7.39 (m, 1H), 
7.45 (m, 1H), 7.94 (m, 1H), 8.10 (m, 2H), 8.32 (s, 1H), 8.35 (d, J = 5.5 Hz, 1H), 9.74 
(s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 14.98, 19.39, 108.13, 116.27, 117.98, 118.89, 
122.22, 129.64, 141.78, 145.19, 153.46, 158.25, 159.48, 159.96, 169.45; HRMS (m/z): 
[M+H]+ calcd for C16H19N6O2S2, 391.1011; found, 391.1007. 
3-[4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-ylamino]-benzenesulfonamide 
(3). By condensation of 3-dimethylamino-1-(4-methyl-2-methylamino-thiazol-5-yl)-
propenone and nitrate of 3-guanidino-benzenesulfonamide. Yellow solid; mp: 276-278 
°C; anal. RP-HPLC (0-60% MeCN): tR = 11.8 min; 1H-NMR (500 MHz, DMSO-d6): δ 2.73 
(s, 3H), 3.12 (d, , J = 5.0 Hz, 3H), 7.20 (d, J = 6.0 Hz, 1H), 7.52 (s, 2H), 7.65 (d, J = 
8.0 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.29 (m, 1H), 8.59 (br s, 
1H), 8.61 (d, J = 6.0 Hz, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 19.8, 31.9, 107.98, 
112.50, 116.33, 118.32, 119.01, 122.22, 129.64, 141.77, 145.20, 153.52, 158.28, 
159.45, 159.95; HRMS (m/z): [M+H]+ calcd for C15H17N6O2S2, 377.0854; found, 
377.0857. 
N-Methyl-3-[4-(4-methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-ylamino]-benzene-
sulfonamide (4). By condensation of 3-dimethylamino-1-(4-methyl-2-methylamino-
thiazol-5-yl)-propenone and nitrate of 3-guanidino-N-methyl-benzenesulfonamide. Yellow 
solid; mp: 243-245 °C; anal. RP-HPLC (0-60% MeCN): tR = 13.2 min; 1H-NMR (500 MHz, 
DMSO-d6): δ 2.53 (s, 3H), 2.57 (d, J = 5.0 Hz, 3H), 2.99 (s, 3H), 7.00 (d, J = 5.5 Hz, 
1H), 7.44 (d, J = 8.0Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 8.33 (d, 
J = 5.5 Hz, 1H), 8.52 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 19.34, 29.46, 31.63, 
108.08, 117.12, 118.29, 119.51, 122.66, 129.89, 140.35, 142.01, 153.54, 158.28, 
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159.40, 159.87, 170.47. HRMS (m/z): [M+H]+ calcd for C16H19N6O2S2, 391.1011; found, 
391.1007. 
3-[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-ylamino]-N-methyl-benzenesulfon-
amide (5). By condensation of 1-(2-amino-4-methyl-thiazol-5-yl)-3-dimethylamino-
propenone and nitrate of 3-guanidino-N-methyl-benzenesulfonamide. Yellow solid; mp: 
206-208 °C; anal. RP-HPLC (0-60% MeCN: tR = 15.9 min; 1H-NMR (500 MHz, DMSO-d6): 
δ 2.43 (s, 3H), 2.44 (s, 3H), 7.14 (d, J = 5.5 Hz, 1H), 7.35 (m, 1H), 7.52 (t, J = 8.0 Hz, 
1H), 7.98 (d, J = 8.0 Hz, 1H), 8.30 (s, 1H), 8.58 (d, J = 5.5 Hz, 1H); 13C-NMR (125 MHz, 
DMSO-d6): δ 18.54, 19.65, 29.43, 109.85, 117.40, 119.91, 122.89, 130.02, 131.14, 
140.40, 141.65, 152.98, 158.74, 160.07, 167.22; HRMS (m/z): [M]+ calcd for 
C15H16N6O2S2, 376.0776; found, 376.0774. 
(3-Methanesulfonyl-phenyl)-[4-(4-methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-yl]-
amine (6). By condensation of 3-dimethylamino-1-(4-methyl-2-methylamino-thiazol-5-
yl)-propenone and N-(3-methanesulfonyl-phenyl)-guanidine nitrate. Light yellow solid; 
mp: 272-274 °C; anal. RP-HPLC (0-60% MeCN): tR = 13.8 min; 1H-NMR (500 MHz, 
DMSO-d6): δ 2.86 (s, 3H), 2.87 (s, 3H), 3.20 (s, 3H), 6.98 (d, J = 5.5 Hz, 1H), 7.46 (d, J 
= 7.5 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.95 (m, 1H), 8.08 (m, 1H), 8.38 (d, J = 5.0 Hz, 
1H), 8.54 (s, 1H), 9.87 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 19.33, 31.69, 44.47, 
108.11, 116.72, 118.29, 119.77, 123.78, 130.15, 141.87, 142.24, 153.64, 158.37, 
159.29, 159.78, 161.53; HRMS (m/z): [M+H]+ calcd for C16H18N5O2S2, 376.0902; found, 
376.0902. 
[4-(2-Ethylamino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-methanesulfonyl-phenyl)-
amine (7). By condensation of 3-dimethylamino-1-(2-ethylamino-4-methyl-thiazol-5-yl)-
propenone and N-(3-methanesulfonyl-phenyl)-guanidine nitrate. Light yellow solid; mp: 
220-221 °C; anal. RP-HPLC (0-60% MeCN): tR = 14.6 min; 1H-NMR (500 MHz, DMSO-
d6): δ 1.19 (t, J = 7.0 Hz, 3H), 2.48 (s, 3H), 2.63-3.17 (m, 5H), 6.97 (d, J = 5.5 Hz, 
1H), 7.47 (d, J = 7.5 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.94 (m, 1H), 8.16 (m, 1H), 8.38 
(d, J = 5.0 Hz, 1H), 8.51 (s, 1H), 9.86 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 14.93, 
19.36, 44.48, 46.00, 108.19, 116.74, 117.94, 119.78, 123.80, 130.17, 141.87, 142.27, 
153.60, 158.34, 159.35, 159.80, 169.51; HRMS (m/z): [M+H]+ calcd for C17H20N5O2S2, 
390.1058; found, 390.1060. 
3-[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-ylamino]-N-ethyl-benzenesulfon-
amide (8). By condensation of 1-(2-amino-4-methyl-thiazol-5-yl)-3-dimethylamino-
propenone and nitrate of N-ethyl-3-guanidino-benzenesulfonamide. Yellow solid; mp: 
176-177 °C; anal. RP-HPLC (0-60 % MeCN%): tR = 13.5 min; 
1H-NMR (500 MHz, DMSO-
d6): δ 1.08 (t, J = 7.5 Hz, 3H), 2.51 (s, 3H), 2.95 (m, 2H), 6.98 (d, J = 5.5 Hz, 1H), 
7.44-7.49 (m, 2H), 7.89 (d, J = 7.5 Hz, 1H), 8.34 (d, J = 5.5 Hz, 1H), 8.37 (br s, 1H); 
HRMS (m/z): [M+H]+ calcd for C16H19N6O2S2, 391.1011; found, 391.1007. 
[4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-yl]-[4-methyl-3-(morpholine-4-
sulfonyl)-phenyl]-amine (9). By condensation of 3-dimethylamino-1-(4-methyl-2-
methylamino-thiazol-5-yl)-propenone and N-[4-methyl-3-(morpholine-4-sulfonyl)-
phenyl]-guanidine nitrate. Light yellow solid; mp: 237-238 °C; anal. RP-HPLC (0-60% 
MeCN): tR = 15.8 min; 1H-NMR (500 MHz, DMSO-d6): δ 2.53 (s, 3H), 2.59 (s, 3H), 2.99 
(s, 3H), 3.16 (m, 4H), 3.70 (m, 4H), 6.97 (d, J = 5.5 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 
7.80 (d, J = 8.0 Hz, 1H), 8.31 (d, J = 5.0 Hz, 1H), 8.41 (s, 1H); 13C-NMR (125 MHz, 
DMSO-d6): δ 19.38, 20.38, 31.61, 46.03, 66.30, 108.02, 118.29, 119.89, 123.51, 
129.75, 133.71, 135.34, 139.74, 153.47, 158.27, 159.50, 159.94, 170.38. HRMS (m/z): 
[M+H]+ calcd for C20H25N6O3S2, 461.1430; found, 461.1433. 
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-[4-methyl-3-(morpholine-4-
sulfonyl)-phenyl]-amine (10). By condensation of 1-(2-amino-4-methyl-thiazol-5-yl)-3-
dimethylamino-propenone and N-[4-methyl-3-(morpholine-4-sulfonyl)-phenyl]-guanidine 
nitrate. Light yellow solid; mp: 183-184 °C; anal. RP-HPLC (0-60% MeCN): tR = 15.5 
min. 1H-NMR (500 MHz, DMSO-d6): δ 2.76 (s, 3H), 2.82 (s, 3H), 3.38 (m, 4H), 3.95 (m, 
4H), 7.23 (d, J = 5.5 Hz, 1H), 7.66 (d, J = 9.0 Hz, 1H), 7.83 (s, 2H), 8.41 (m, 1H), 8.66 
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(d, J = 5.0 Hz, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 19.16, 20.33, 46.03, 66.32, 
108.31, 118.33, 120.11, 123.47, 129.70, 133.66, 135.41, 139.72, 153.12, 158.24, 
159.63, 159.95, 169.62. HRMS (m/z): [M+H]+ calcd for C19H23N6O3S2, 447.1273; found  
447.1271. 
4-[4-(3,4-Dimethyl-2-oxo-2,3-dihydro-thiazol-5-yl)-pyrimidin-2-ylamino]-N-(2-
methoxy-ethyl)-benzenesulfonamide (11). By condensation of 5-(3-dimethylamino-
acryloyl)-3,4-dimethyl-3H-thiazol-2-one and nitrate of 4-guanidino-N-(2-methoxy-ethyl)-
benzenesulfonamide; Yellow solid; mp: 238-239 °C; anal. RP-HPLC (0-60% MeCN): tR = 
16.3 min; 1H-NMR (500 MHz, DMSO-d6): δ 2.52 (s, 3H), 2.82 (q, J = 6.0, 12.0 Hz, 2H), 
3.10 (s, 3H), 3.23 (m, 2H), 3.25 (s, CH3), 7.00 (d, J = 5.5 Hz, 1H), 7.43 (t, J = 6.0 Hz, 
1H), 7.64 (d, J = 9.0 Hz, 2H), 7.87 (d, J = 9.0 Hz, 2H), 8.44 (d, J = 5.5 Hz, 1H); 13C-
NMR (125 MHz, DMSO-d6): δ 15.02, 30.35, 42.83, 58.56, 71.25, 110.08, 110.24, 
118.85, 128.12, 133.08, 139.03, 144.63, 158.61, 159.30, 159.77, 170.37; HRMS (m/z): 
[M+H]+ calcd for C18H22N5O4S2, 436.1113; found 436.1111. 
3-[4-(3,4-Dimethyl-2-oxo-2,3-dihydro-thiazol-5-yl)-pyrimidin-2-ylamino]-benzonitrile 
(12). By treatment of 5-(3-dimethylamino-acryloyl)-3,4-dimethyl-3H-thiazol-2-one and 
N-(3-cyano-phenyl)-guanidine nitrate; anal. RP-HPLC (10-70% MeCN): tR = 15.5 min; 
1H-NMR (500 MHz, DMSO-d6): δ 2.52 (s, 3H), 3.29 (s, 3H), 7.06 (d, J = 5.5 Hz, 1H), 
7.40 (m, 1H), 7.51 (t, J = 8.0 Hz, 1H), 7.93 (m, 1H), 8.33 (s, 1H), 8.50 (d, J = 5.5 Hz, 
1H), 10.00 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 14.97, 30.32, 109.94, 109.95, 
112.05, 119.76, 121.89, 124.04, 125.43, 130.61, 139.02, 141.91, 158.55, 159.34, 
159.78, 170.36; HRMS (m/z): [M+H]+ calcd for C16H14N5OS, 324.0919; found 324.0927. 
3,4-Dimethyl-5-[2-(4-methyl-3-nitro-phenylamino)-pyrimidin-4-yl]-3H-thiazol-2-one 
(13). By condensation of 5-(3-dimethylamino-acryloyl)-3,4-dimethyl-3H-thiazol-2-one 
and N-(3-cyano-4-methyl-phenyl)-guanidine nitrate; anal. RP-HPLC (10-70% MeCN): tR 
= 17.6 min; 1H-NMR (500 MHz, DMSO-d6): δ 2.44 (s, 3H), 2.55 (s, 3H), 3.28 (s, 3H), 
7.03 (d, J = 5.5 Hz, 1H), 7.40 (d, J = 9.0 Hz, 1H), 7.84 (d, J = 9.0 Hz, 1H), 8.48 (d, J = 
5.5 Hz, 1H,), 8.59 (s, 1H), 9.99 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 14.96, 19.70, 
30.32, 109.79, 114.22, 124.13, 125.63, 133.42, 138.94, 140.07, 149.44, 158.54, 
159.33, 159.80, 170.41; HRMS (m/z): [M+H]+ calcd for C16H16N5O3S, 358.0974; found, 
358.0976. 
3,4-Dimethyl-5-[2-(4-piperazin-1-yl-phenylamino)-pyrimidin-4-yl]-3H-thiazol-2-one 
(14). A solution of potassium thiocyanate (5.67 g, 58 mmol) in Me2CO (45 mL) was 
cooled on ice and 3-chloro-pentane-2,4-dione (6.95 mL, 58 mmol) was added dropwise. 
The mixture was warmed to room temperature and stirred for 6 h. After evaporation to 
dryness, the residue was dissolved in EtOH (30 mL) and conc. aq HCl (15 mL) was 
added. This mixture was heated to reflux for 14 h. After cooling, it was concentrated and 
the resulting precipitates were filtered and washed successively with cold MeOH and Et2O 
to afford 5-acetyl-4-methyl-3H-thiazol-2-one (9.1 g, 100%). mp 208-211 °C; anal. RP-
HPLC (10-70% MeCN): tR = 6.5 min; 1H-NMR (500 MHz, CDCl3): δ 2.33 (s, 3H), 2.38 (s, 
3H), 11.9 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 15.06, 29.94, 115.53, 142.99, 
170.92, 189.91; FTIR: 3094, 2850, 1669, 1622, 1579 cm-1; MS (m/z): [M+H]+ calcd for 
C6H8NO2S, 158.19; found 157.77. 
5-Acetyl-4-methyl-3H-thiazol-2-one (4.64 g, 27.1 mmol) and N,N-dimethylformamide 
dimethylacetal (8.4 mL, 59.6 mmol) were mixed in a dry, Ar-flushed flask, and the mix-
ture was heated at 100 °C for 3 h. After cooling, an equal volume of Et2O was added. The 
resulting orange solid was filtered and washed with Et2O to afford 2.73 g of 5-(3-
dimethylamino-acryloyl)-3,4-dimethyl-3H-thiazol-2-one as an orange solid. 1H-NMR (500 
MHz, DMSO-d6): δ 2.52 (s, 3H), 2.82 (br s, 3H), 3.11 (br s, 3H), 3.22 (s, 3H), 5.10 (d, J 
= 12.2Hz, 1H,), 7.61 (d, J = 11.7 Hz, 1H). 
N-[4-(4-Acetyl-piperazin-1-yl)-phenyl]-guanidine nitrate was prepared following the 
procedures described previously (Wang et al., 2004a). The reaction mixture was filtered 
through Celite and concentrated under reduced pressure. Recrystallisation from EtOH 
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gave the pure product as a pale pink solid (91%). 1H-NMR (500 MHz, DMSO-d6): δ 2.06 
(s, 3H), 3.15 (m, 4H), 3.58 (m, 4H), 7.04-7.19 (m, 8H), 9.32 (s, 1H). 
A solution of 5-(3-dimethylamino-acryloyl)-3,4-dimethyl-3H-thiazol-2-one (0.20 g, 0.88 
mmol), N-[4-(4-acetyl-piperazin-1-yl)-phenyl]-guanidine nitrate (0.38 g, 1.15 mmol) and 
NaOH (0.09 g, 2.3 mmol) in 2-methoxylethanol (15 mL) was heated at 120 °C for 20 h. 
The reaction mixture was evaporated to dryness and the residue was purified by silica gel 
chromatography, eluting with CH2Cl2, then 2% MeOH/CH2Cl2 to afford 5-[2-[4-(4-acetyl-
piperazin-1-yl)-phenylamino]-pyrimidin-4-yl]-3,4-dimethyl-3H-thiazol-2-one as a yellow 
solid (0.22 g, 60 %). Mp. 231-234 °C; anal. RP-HPLC (10-70% MeCN): tR = 9.5 min; 1H-
NMR (500 MHz, DMSO-d6): δ 2.03 (s, 3H), 2.55 (s, 3H), 3.01 (m, 2H), 3.08 (m, 2H), 
3.29 (s, 3H), 3.57 (m, 4H), 6.87 (d, J = 5.5 Hz, 1H), 6.93 (d, J = 9.0 Hz, 2H), 7.58 (d, J 
= 9.0 Hz, 2H), 8.37 (d, J = 5.5 Hz, 1H), 9.37 (s, 1H); Analysis (calcd, found for 
C21H24N6O2S): C (58.41, 58.49), H (5.70, 5.77), N (19.80, 19.33). 
This material, in 2 M HCl in EtOH, was heated under reflux for 2.5 h. After cooling, the 
mixture was evaporated, the residue was basified by addition of 2 M aq NaOH and ex-
tracted (2 × 50 mL CH2Cl2). The combined extracts were washed with brine, dried on 
MgSO4, and filtered. The solvent was evaporated and the residue was crystallised from 
MeOH to afford 3,4-dimethyl-5-[2-(4-piperazin-1-yl-phenylamino)-pyrimidin-4-yl]-3H-
thiazol-2-one (14) as a yellow solid (90%). mp. 224-226 °C; anal. RP-HPLC (0-60% 
MeCN): tR = 10.9 min; 1H-NMR (500 MHz, DMSO-d6): δ 2.57 (s, 3H), 3.10 (m, 4H), 3.16 
(m, 4H), 3.36 (s, 3H), 6.65 (d, J = 5.5 Hz, 1H), 6.94 (d, J = 10.5 Hz, 2H), 7.47 (d, J = 
9.0 Hz, 2H), 8.31 (d, J = 5.5 Hz, 1H); 13C-NMR (125 MHz, DMSO-d6): δ 14.85, 30.20, 
46.35, 50.84, 108.18, 110.62, 116.36, 121.11, 132.83, 138.18, 147.69, 158.38, 159.13, 
160.33, 170.42. Analysis (calcd, found for C19H22N6OS·0.45 H2O): C (59.55, 59.32), H 
(6.10, 6.14), N (25.59, 24.97). 
Cloning, expression, and purification of His-tagged CDK9/Cyclin T1 
Cloning and expression of His-tagged CDK9/cyclin T1. Baculoviral transfer vector 
pFastBac HTa (Invitrogen, Carlsbad, USA) was modified to produce pSSP1, by replacing 
the region between the Rsr II and Eco RI restriction endonuclease sites of pFastBac HTa 
with a double stranded linker corresponding to sense strand 5’-GTCCGTCCGAAACCAT 
GTCGTACTACCATCACCATCACCATCACGGTATGGCTAGCGACGATGACGATAAGGGATCCGTGC
GGCCGCG-3’. This modification was introduced to allow expression of fusion proteins 
where the N-terminal polyhistidine tag (His-tag) could be removed by cleavage at an en-
tertokinase cleavage site introduced immediately adjacent to the polypeptide encoded by 
the inserted gene of interest. 
The CDK9 open reading frame was amplified from a human foetal lung 5’-Stretch Plus 
cDNA library (Clontech, Palo Alto, USA) using PCR primer 1 (5'-GCGTTGGAGGCGGCCATG 
GCAAAGCAGTACG-3’) and 2 (5’-CTAGTGGCAAGCGCCGGCCCTCAGAAG-3’). The amplified 
DNA fragment was cloned into pCR4-Topo (Invitrogen, Carlsbad, USA), to give pCR4-
CDK9. PCR primer 3 (5’-GGCGCTAGCGACGATGACGATAAGATGGCAAAGCAGTACGACTCG-
3’) and 4 (5’-CAGGAAACAGCTATGAC-3’) were used to amplify the CDK9 open reading 
frame from pCR4-CDK9. The PCR product generated was digested with Nhe I and Eco RI 
and ligated into pSSP1, also digested with Nhe I and Eco RI. Insert DNA from several 
clones was sequenced, and fragment exchange was used to generate a single clone, 
pSSP1-Cdk9 with the correct CDK9 coding sequence. 
The cyclin T1 open reading frame was amplified as two fragments from a human foetal 
lung 5’-Stretch Plus cDNA library (Clontech, Palo Alto, USA), using PCR primer 5 (5’-
ATGGAGGGAGAGAGGAAGAACAACAACAAACGGTGGTAT-3’) and 6 (5’-GTAAGTGCTAAATTC 
TCACTAGTCCG-3’), or PCR primer 7 (5’-CTACTCAGGG TCATCGGACT AGTGAG-3’) and 8 
(5’-TTACTTAGGAAGGGGTGGAAGTGGTGGAGGAGGTTCTGA-3’). Each of the PCR products 
generated were cloned into pCR4-Topo, giving pCR4-5’Cyclin T1 and pCR4-3’cyclin T1, 
respectively. The sequence of these PCR fragments was confirmed. The cyclin T1 frag-
ment of pCR4-5’cyclin T1 was then amplified using PCR primer 9 (5’-
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GGCGCTAGCGACGATGACGATAAGATGGAGGGAGAGAGGAAGAACAAC-3’) and 4 (5-CAGGA 
AACAGCTATGAC-3’), to introduce an Nhe I restriction endonuclease site upstream of the 
Cyclin T1 coding sequence. The resulting PCR product was digested with Nhe I and Eco 
RI and then ligated into pSSP1, also digested with Nhe I and Eco RI, to give pSSP-
5’cyclin T1. The complete cyclin T1 open reading frame was subsequently generated by 
digesting pCR4-3’cyclin T1 with Not I and Spe I, and ligating the required fragment into 
pSSP-5’cyclin T1, also digested with Not I and Spe I, to create pSSP1-cyclin T1. 
Bacmid DNA and baculoviral stocks were generated from pSSP1-CDK9 and pSSP1-
cyclin T1 according to the manufacturer’s instructions for pFastBac HTa. High-titre bacu-
loviral stocks were generated by amplification in Sf9 cells grown in suspension culture. 
Viral titres were determined by standard plaque assay protocols, as per the manufac-
turer’s instructions. 
His-tagged CDK9 and cyclin T1 were co-expressed following co-infection of Sf9 cells by 
SSP1-CDK9 and SSP1-cyclin T1 baculoviruses. 72 h post-infection, cells were harvested 
by centrifugation, and snap frozen. Recombinant protein expression levels were con-
firmed by western blotting, using CDK9 sc-8338 and cyclinT1 sc-10750 antibodies (Santa 
Cruz Biotechnology, Inc., Santa Cruz, USA). 
Protein Purification. The Sf9 cell pellet from 300 mL cell culture was lysed in 30 mL of 
25 mM HEPES pH 7.5, 0.02 mM EGTA, 0.02 mM EDTA, 270 mM sucrose, 1% Triton X-
100, 0.07% β-mercaptoethanol, 1 mM Na3VO4, 5 mM NaF, 0.2 mM PMSF, 1 mM ben-
zamidine, protease inhibitor cocktail (Sigma, St. Louis, USA ). After incubating on ice for 
20 min, the samples were cleared by centrifuging for 20 min at 15,000 rpm. The result-
ing supernatant was supplemented with NaCl to 0.3 M, and then 1.2 mL (pre-
equilibrated) Ni-NTA beads were added. After 1.5 h constant rotation at 4 oC, samples 
were centrifuged for 2 min at 2,000 rpm and supernatant was removed. Beads were re-
suspended in 10 mL of 25 mM HEPES pH 7.5, 0.02 mM EGTA, 0.02 mM EDTA, 0.5 M 
NaCl, 20 mM imidazole, 0.03% Brij-35, 0.07% β-mercaptoethanol, 0.2 mM PMSF, 1 mM 
benzamidine then and transferred to a 12 mL column. Washing was performed twice with 
10 mL of 25 mM HEPES pH 7.5, 0.02 mM EGTA, 0.02 mM EDTA, 0.5 M NaCl, 20 mM imi-
dazole, 0.03% Brij-35, 0.07% β-mercaptoethanol, 0.2 mM PMSF, 1 mM benzamidine, 
and then twice with 10 mL of 25 mM HEPES pH 7.5, 0.02 mM EGTA, 0.02 mM EDTA, 0.3 
M NaCl, 0.03% Brij-35, 0.07% β-mercaptoethanol, 0.2 mM PMSF, 1 mM benzamidine. 
CDK9/cyclin T1 was eluted with three washes of 2 mL of 25 mM HEPES pH 7.5, 0.02 mM 
EGTA, 0.02 mM EDTA, 0.3 M NaCl, 0.03% Brij-35, 0.07% β-mercaptoethanol, 0.2 mM 
PMSF, 1 mM benzamidine, 200 mM imidazole. CDK9/cyclin T1-containing fractions were 
identified by Western blotting. These fractions were combined and then dialysed over-
night against 100 volumes of 50 mM Tris/HCl pH7.5, 0.1 mM EGTA, 150 mM NaCl, 270 
mM sucrose, 0.03% Brij-35, 0.07% β-mercaptoethanol, 1 mM benzamidine, 0.1 mM 
PMSF. Protein concentration was determined by BCA assay. Samples were snap frozen in 
100 μL aliquots, and stored at -70 °C. Specific activity was determined prior to use in 
screening assays. 
Biopharmaceutical profiling and PK determinations 
Test compound partitioning between octanol and aqueous buffer was carried out using 
the shake-flask method (Dearden, 1985). Compound pKa values were determined using a 
pH-metric titration method (GlpKa; Sirius) (Comer, 2003). Aqueous solubility was as-
sessed by turbidimetric measurements (Brooker et al., 1974). Apparent permeability co-
efficients were measured using a Caco-2 cell layer assay (Gan et al., 1997). In vitro 
phase-I liver metabolism was assessed by disappearance of parent compound (LC-MS 
quantitation) from a preparation of rat liver microsomes (Houston et al., 1997). Rat 
plasma protein binding was determined in an equilibrium dialysis assay (Kariv et al., 
2001). 
For PK measurements 3 male Wistar rats per sample and dose were treated by iv bo-
lus injection or by po gavage of test compound solutions. Blood samples were collected 
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from each rat from the cannulated jugular vein at time zero and at intervals up to 24 h. 
Samples were centrifuged immediately and plasma was harvested and frozen at –20 °C 
until analysis. Quantitative compound level analysis was carried out using LC-MS/MS 
methods. PK parameters were derived by the noncompartmental methods using the 
WinNonlin 3.2 software programme (Pharsight). Oral bioavailability (%F) was calculated 
by taking the ratio of dose-normalised AUC values from oral versus parenteral dosing. 
Evaluation of anti-tumour efficacy 
Murine P388/0 leukaemia model. Six-week-old male CD2F1 mice were implanted in-
traperitoneally with P388/0 leukaemia cells (105) on day 0. On day 1 post-inoculation 
mice were given by ip administration either vehicle or test compound (0.1 mL / 10 g 
body weight) at the dose shown, on a treatment schedule of twice a day for 10 days. The 
effectiveness of treatment was assessed by comparison of the median post-inoculation 
lifespan (ILS) of each group of treated mice with that of the vehicle control group. The 
ILS ratio of the treated and control groups was used as an indicator of efficacy. 
Colo-205 xenograft model. Female athymic ICR SCID mice, 5-6 weeks old on day 1 of 
the treatment, were used for this study. Test animal were implanted subcutaneously on 
day 0 with 30-60 mg tumour fragments using a 12-gauge trocar needle. Treatment be-
gan on day 18 when the mean estimated tumour mass for all groups in the study was 
107 mg (range 97-115 mg). The animals were assigned into the treatment and the con-
trol groups with 10 mice per group. All animals were observed for clinical signs at least 
once daily. Tumour size was measured at least twice weekly. Animals were terminated at 
any time during the study if the tumour size became excessive or any adverse effects 
were noted. The treatments were administered by ip injection or po gavage daily, staring 
on day 18, and continuing for 8 days. The tumour burden (mg) was estimated from calli-
per measurements using the formula for the volume of a prolate ellipsoid assuming unit 
density. The mean tumour mass on the day of randomisation was reported for each 
group. Calculations of relative tumour mass and plot of mean tumour growth curves were 
performed. The relative tumour mass data from each group were compared using a one-
way analysis of variance (ANOVA) and statistical significance was determined using the 
built-in data analysis tools in Microsoft Excel and R (The R Project for Statistical Comput-
ing). 
Crystallography 
Human recombinant CDK2 was expressed, purified, and crystallised as previously de-
scribed (Wu et al., 2003). Data were collected at the Cyclacel home source with a FR-D 
X-ray generator using a Raxis IV++ image plate (Rigaku). Data processing was carried 
out using the d*TREK software suite (Pflugrath, 1999). The structures were solved by 
molecular replacement using MOLREP (Vagin et al., 1997) and PDB entry 1PW2. 
ARP/wARP (Lamzin et al., 1997) was used for initial density interpretation and the addi-
tion of water molecules. REFMAC (Murshudov et al., 1997) was used for structural re-
finement. A number of rounds of refinement and model building with the programme 
COOT (Emsley et al., 2010) were carried out. All the crystallographic programmes used 
were part of the CCP4 programme suite (Potterton et al., 2004). The coordinates of the 
X-ray crystal structures of compounds 11 and 14 in complex with CDK2 have been de-
posited with the PDB (www.rcsb.org) under accession codes 2XMY and 2XNB. 
Supplemental References 
Brooker, P.J., and Ellison, M. (1974). Determination of the water solubility of organic 
compounds by a rapid turbidimetric method. Chem. Ind., 285-287. 
14 
Comer, J.E.A. (2003). High-throughput measurement of log D and pKa. Methods 
Principles Med. Chem. 18, 21-45. 
Dearden, J.C. (1985). Partitioning and lipophilicity in quantitative structure-activity 
relationships. Environ. Health Persp. 61, 203-228. 
Gan, L.-S.L., and Thakker, D.R. (1997). Applications of the Caco-2 model in the design 
and development of orally active drugs: elucidation of biochemical and physical barriers 
posed by the intestinal epithelium. Adv. Drug Delivery Rev. 23, 77-98. 
Houston, J.B., and Carlile, D.J. (1997). Prediction of hepatic clearance from microsomes, 
hepatocytes, and liver slices. Drug Metabol. Rev. 29, 891-922. 
Kariv, I., Cao, H., and Oldenburg, K.R. (2001). Development of a high throughput 
equilibrium dialysis method. J. Pharm. Sci. 90, 580-587. 
Lamzin, V.S., and Wilson, K.S. (1997). Automated refinement for protein crystallography. 
Methods Enzymol. 277, 269-305. 
Murshudov, G.N., Vagin, A.A., and Dodson, E.J. (1997). Refinement of macromolecular 
structures by the maximum-likelihood method. Acta Crystallogr. D53, 240-255. 
Pflugrath, J.W. (1999). The finer things in X-ray diffraction data collection. Acta 
Crystallogr. D55 1718-1725. 
Potterton, L., McNicholas, S., Krissinel, E., Gruber, J., Cowtan, K., Emsley, P., 
Murshudov, G.N., Cohen, S., Perrakis, A., and Noble, M. (2004). Developments in the 
CCP4 molecular-graphics project. Acta Crystallogr. D60, 2288-2294. 
Vagin, A., and Teplyakov, A. (1997). MOLREP: an automated program for molecular 
replacement. J. Appl. Crystallogr. 30, 1022 -1025. 
Wang, S., Meades, C., Wood, G., Osnowski, A., Anderson, S., Yuill, R., Thomas, M., 
Mezna, M., Jackson, W., Midgley, C., Griffiths, G., Fleming, I., Green, S., McNae, I., Wu, 
S.-Y., McInnes, C., Zheleva, D., Walkinshaw, M.D., and Fischer, P.M. (2004a). 2-Anilino-
4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR analysis, X-Ray 
Crystallography, and Biological Activity. J. Med. Chem. 47, 1662-1675. 
Wang, S., Wood, G., Meades, C., Griffiths, G., Midgley, C., McNae, I., McInnes, C., 
Anderson, S., Jackson, W., Mezna, M., Yuill, R., Walkinshaw, M., and Fischer, P.M. 
(2004b). Synthesis and Biological Activity of 2-Anilino-4-(1H-pyrrol-3-yl)pyrimidine CDK 
Inhibitors. Bioorg. Med. Chem. Lett. 14, 4237-4240. 
Wu, S.Y., McNae, I., Kontopidis, G., McClue, S.J., McInnes, C., Stewart, K.J., Wang, S., 
Zheleva, D.I., Marriage, H., Lane, D.P., Taylor, P., Fischer, P.M., and Walkinshaw, M.D. 
(2003). Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS: 
Structural Basis for Ligand-Induced Disordering of the Activation Loop. Structure 11, 
399-410. 
 
 
